Zobrazeno 1 - 10
of 10 216
pro vyhledávání: '"transarterial chemoembolization."'
Publikováno v:
Паёми Сино, Vol 26, Iss 4, Pp 694-699 (2024)
The article presents a clinical case of successful treatment of a patient with a BCLC stage B hepatocellular carcinoma (HCC), with the initial prediction of unfavorable radical treatment results and poor outcomes. The described approach allows the ac
Externí odkaz:
https://doaj.org/article/8caf3f8feadb406f9a9225e2d6002578
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2441-2452 (2024)
Yu-Tang Chen,1,2,* Bo-Wen-Tao Chen,3,* Jun-Ming Xu,1,4,* Xiao-Cui You,1 Yi Tang,3 Shao-Jie Wu,3 Zhu-Ting Fang1,3 1Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Ca
Externí odkaz:
https://doaj.org/article/9e061598b2b64e1694c42a4ac7779b03
Autor:
Reham Ashour, Eman Rewisha, Mohamed AKL Rady, Sally Waheed Elkhadry, Heba Abdelhalim, Mohamed Atef
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Background Switching to systemic therapy after transarterial chemoembolization (TACE) refractoriness is more inclined to preserve liver function and decrease disease progression. Hence, we conducted a comparison between the advantages of sor
Externí odkaz:
https://doaj.org/article/c986d517cc604dcfb46cad2fb6ae7a16
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2321-2337 (2024)
Chendong Wang,1,* Bin Leng,1,* Ran You,1,* Zeyu Yu,1 Ya Lu,1 Lingfeng Diao,1 Hao Jiang,1 Yuan Cheng,2 Guowen Yin,1 Qingyu Xu1 1Department of Interventional Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affil
Externí odkaz:
https://doaj.org/article/d5d630edfb4146bb9be2c2b1065fb22a
Autor:
Jin M, Jiang ZQ, Qin JH, Qin HX, Jiang KW, Ya HX, Gu J, Gui MR, Li YH, Xu LK, Fu HX, Xiao XH, Li SQ
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2309-2320 (2024)
Ming Jin,1,* Zhi-qing Jiang,2,* Jia-hui Qin,3,* Hui-xia Qin,4,* Kai-wen Jiang,3,* Hou-xiang Ya,3 Jing Gu,3 Mo-rui Gui,5 Yao-hua Li,3 Long-kuan Xu,6 Hai-xiao Fu,6 Xu-hua Xiao,7 Shu-qun Li3 1Department of Vascular Intervention, Affi
Externí odkaz:
https://doaj.org/article/de755f3d18494613bb0939e02f5709e0
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Objective The aim of this study was to investigate the efficacy and safety of the combined treatment regimen of D-TACE, HAIC, and Lenvatinib in patients with massive hepatocellular carcinoma, with the goal of providing a safer and more effec
Externí odkaz:
https://doaj.org/article/69a5980219534c8ea41ebfa8ed891f8d
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background A majority of esophageal carcinoma patients are diagnosed at an advanced stage and are no longer suitable for surgical resection. Drug-eluting beads transarterial chemoembolization (DEB-TACE) with oxaliplatin-loaded CalliSpheres b
Externí odkaz:
https://doaj.org/article/0d5652cdfd27419dbae2e663234f0528
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Korsic Spela, Osredkar Josko, Smid Alojz, Steblovnik Klemen, Popovic Mark, Locatelli Igor, Trontelj Jurij, Popovic Peter
Publikováno v:
Radiology and Oncology, Vol 58, Iss 4, Pp 517-526 (2024)
Transarterial chemoembolization (TACE) is the treatment of choice for the intermediate stage hepatocellular carcinoma (HCC). Doxorubicin remains the most used chemotherapeutic agent in TACE, although in vitro screening has demonstrated that idarubici
Externí odkaz:
https://doaj.org/article/b057c4fc8cf84aeb9fc7afaa7cd104e2
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2087-2099 (2024)
Rongce Zhao,1,* Jing Zhou,2,* Zehao Zheng,1,* Xinhao Xiong,1 Qiaoxuan Wang,3 Shaohua Li,1 Wei Wei,1 Rongping Guo1 1Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Me
Externí odkaz:
https://doaj.org/article/a89704e0b3f640bb86711ca6a4143e59